Author/Authors :
Anoun, S 20 Aout Hospital - Hematology pediatric oncology department, Morocco , Lamchahab, M 20 Aout Hospital - Hematology pediatric oncology department, Morocco , Qachouh, M 20 Aout Hospital - Hematology pediatric oncology department, Morocco , Benchekroun, S 20 Aout Hospital - Hematology pediatric oncology department, Morocco , Quessar, A 20 Aout Hospital - Hematology pediatric oncology department, Morocco
Abstract :
Methotrexate is an anti-rheumatic agent used as a first-line treatment for rheumatoid arthritis. Hematological malignancies like lymphoma or acute myeloid leukemia have been reported to be secondary to treatment with Methotrexate, but are very uncommon. We report here the first Moroccan case of RA patient on low dose MTX, who developed AML. We also reviewed all similar cases.
